Go Premium in Our Biggest Sale Ever

Go Ultimate 75% OFF

DE:1FW2 Stock Latest News

The FlyWuXi Biologics price target raised to HK$62 from HK$51.10 at UBS2M ago

RatingsWuXi Biologics: Upgraded Growth Outlook and Higher DCF-Based Target Price Support Buy Rating2M ago
Company AnnouncementsWuXi Biologics Schedules Conference Calls to Present 2026 Interim Results2M ago
Company AnnouncementsWuxi Biologics Posts Strong Interim Growth as Integrated Biologics Project Portfolio Expands2M ago
Company AnnouncementsWuXi Biologics sets August board meeting to approve interim 2026 results3M ago

WuXi Biologics Wins Full Shareholder Backing at 2026 AGM

Company AnnouncementsWuXi Biologics Wins Full Shareholder Backing at 2026 AGM5M ago

Company AnnouncementsWuxi Biologics Grants Time-Based Restricted Shares to 21 Employees5M ago

Company AnnouncementsWuXi Biologics Schedules 2026 Business Update Calls for Investors5M ago

Company AnnouncementsWuXi Biologics Launches US$400 Million Share Buyback Plan5M ago
Company AnnouncementsWuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate5M ago
RatingsWuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating7M ago
Company AnnouncementsWuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme7M ago

WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors

Company AnnouncementsWuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors7M ago

Company AnnouncementsWuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands7M ago

Company AnnouncementsWuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains9M ago

Company AnnouncementsWuXi Biologics Sets March 24 Board Meeting to Approve 2025 Annual Results9M ago
Company AnnouncementsWuXi Biologics’ Substantial Shareholder to Cut Stake via HK$38.52 Block Trade10M ago
Company AnnouncementsCitigroup-Backed HK$4.00 Cash Offer Launched for Wuxi Biologics Shares at 99% Premium10M ago
Company AnnouncementsWuXi Biologics Highlights Strong 2025 Pipeline and Growth Ahead of J.P. Morgan Healthcare Conference10M ago

Wuxi Biologics Proposes Revised Cap and Renewal of Service Agreement Amid Growing Demand

Company AnnouncementsWuxi Biologics Proposes Revised Cap and Renewal of Service Agreement Amid Growing Demand1y ago

Company AnnouncementsWuxi Biologics Reports Strong Growth in H1 20251y ago

Company AnnouncementsWuXi Biologics to Present 2025 Interim Results in Upcoming Conference Calls1y ago